Literature DB >> 25521877

Awareness of HCV infection among persons who inject drugs in San Diego, California.

Melissa G Collier1, Sandeep K Bhaurla, Jazmine Cuevas-Mota, Richard F Armenta, Eyasu H Teshale, Richard S Garfein.   

Abstract

We asked persons who inject drugs questions about HCV, including past testing and diagnosis followed by HCV testing. Of 540 participants, 145 (27%) were anti-HCV positive, but of those who were positive, only 46 (32%) knew about their infection. Asking about previous HCV testing results yielded better results than did asking about prior HCV diagnosis. Factors associated with knowing about HCV infection included older age, HIV testing, and drug treatment. Comprehensive approaches to educating and screening this population for HCV need implementation.

Entities:  

Mesh:

Year:  2015        PMID: 25521877      PMCID: PMC4318317          DOI: 10.2105/AJPH.2014.302245

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  12 in total

1.  HCV infection prevalence lower than expected among 18-40-year-old injection drug users in San Diego, CA.

Authors:  Richard S Garfein; Amanda Rondinelli; Richard F W Barnes; Jazmine Cuevas; Mitcheal Metzner; Michele Velasquez; David Rodriguez; Meredith Reilly; Jian Xing; Eyasu H Teshale
Journal:  J Urban Health       Date:  2013-06       Impact factor: 3.671

2.  A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C.

Authors:  Mary H Latka; Holly Hagan; Farzana Kapadia; Elizabeth T Golub; Sebastian Bonner; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; Minya Pu; Dave L Thomas; Thelma K Thiel; Steffanie A Strathdee
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

3.  Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.

Authors:  Julie Bruneau; Geng Zang; Michal Abrahamowicz; Didier Jutras-Aswad; Mark Daniel; Elise Roy
Journal:  Clin Infect Dis       Date:  2013-12-20       Impact factor: 9.079

4.  A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen.

Authors:  Kaori Morota; Ryo Fujinami; Hideki Kinukawa; Taiji Machida; Kenichi Ohno; Haruhisa Saegusa; Katsumichi Takeda
Journal:  J Virol Methods       Date:  2009-01-20       Impact factor: 2.014

5.  Risks of a range of alcohol intake on hepatitis C-related fibrosis.

Authors:  Alexander Monto; Keyur Patel; Alan Bostrom; Stephen Pianko; Paul Pockros; John G McHutchison; Teresa L Wright
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

6.  The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users.

Authors:  Carol F Kwiatkowski; Karen Fortuin Corsi; Robert E Booth
Journal:  Addiction       Date:  2002-10       Impact factor: 6.526

7.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

9.  Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA.

Authors:  J M Pawlotsky; A Fleury; V Choukroun; L Deforges; F Roudot-Thoraval; P Aumont; J Duval; D Dhumeaux
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

10.  Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2012-11-09
View more
  5 in total

1.  Sub-optimal Testing and Awareness of HCV and HBV Among High Risk Individuals at an Underserved Safety-Net Hospital.

Authors:  Robert J Wong; Brendan Campbell; Benny Liu; Rachel Baden; Taft Bhuket
Journal:  J Community Health       Date:  2018-02

2.  HCV communication within ego-centric networks of men and women who inject drugs.

Authors:  Marisa Felsher; Karin E Tobin; Mark Sulkowski; Carl Latkin; Oluwaseun Falade-Nwulia
Journal:  Drug Alcohol Depend       Date:  2021-10-29       Impact factor: 4.492

3.  The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.

Authors:  Zameer Mohamed; John Rwegasha; Jin U Kim; Yusuke Shimakawa; Lila Poiteau; Stéphane Chevaliez; Sanjay Bhagani; Simon D Taylor-Robinson; Mark R Thursz; Jessie Mbwambo; Maud Lemoine
Journal:  J Viral Hepat       Date:  2018-07-30       Impact factor: 3.728

Review 4.  Accelerating the elimination of hepatitis C in Kuwait: An expert opinion.

Authors:  Fuad Hasan; Ahmad Alfadhli; Abeer Al-Gharabally; Mahmoud Alkhaldi; Massimo Colombo; Jeffrey V Lazarus
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

5.  HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco.

Authors:  Kimberly Page; Jennifer L Evans; Judith A Hahn; Peter Vickerman; Stephen Shiboski; Meghan D Morris
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.